RESUMEN
The timing of the fruit-set stage (i.e., start and end of fruit set) is crucial in a plant's life cycle, but its response to temperature change is still unclear. We investigated the timing of seven phenological events, including fruit-set dates during 3 yr for six alpine plants transplanted to warmer (approximately +3.5°C in soils) and cooler (approximately -3.5°C in soils) locations along an altitudinal gradient in the Tibetan area. We found that fruit-set dates remained relatively stable under both warming and cooling during the 3-yr transplant experiment. Three earlier phenological events (emergence of first leaf, first bud set, and first flowering) and two later phenological events (first leaf coloring and complete leaf coloring) were earlier by 4.8-8.2 d/°C and later by 3.2-7.1 d/°C in response to warming. Conversely, cooling delayed the three earlier events by 3.8-6.9 d/°C and advanced the two later events by 3.2-8.1 d/°C for all plant species. The timing of the first and/or last fruit-set dates, however, did not change significantly compared to earlier and later phenological events. Statistical analyses also showed that the dates of fruit set were not significantly correlated or had lower correlations with changes of soil temperature relative to the earlier and later phenological events. Alpine plants may thus acclimate to changes in temperature for their fruiting function by maintaining relatively stable timings of fruit set compared with other phenological events to maximize the success of seed maturation and dispersal in response to short-term warming or cooling.
Asunto(s)
Frutas , Temperatura , Cambio Climático , Frío , Ecología , Hojas de la Planta , Fenómenos Fisiológicos de las Plantas , Reproducción , Estaciones del AñoRESUMEN
It has been documented that cardiac agents may regulate the lipid metabolism through increased expression of PPARδ in cardiac cells. However, the effect on lipid metabolism by direct activation of PPARδ is still unknown. The present study applied specific PPARδ agonist (GW0742) to investigate this point in the heart of Wistar rats and in the primary cultured cardiomyocytes from neonatal rat. Expressions of PPARδ in the heart and cardiomyocytes after treatment with GW0742 were detected using Western blots. The fatty acid (FA) oxidation and the citric acid (TCA) cycle related genes in cardiomyocytes were also examined. In addition, PPARδ antagonist (GSK0660) and siRNA-PPARδ were employed to characterize the potential mechanisms. After a 7-day treatment with GW0742, expressions of PPARδ in the heart were markedly increased. Increased expressions of FA oxidation and TCA cycle related genes were also observed both in vivo and in vitro. This action of GW0742 was blocked by GSK0660 or by siRNA-PPARδ. The obtained results show that activation of PPARδ by GW0742 is responsible for the increase of FA oxidation and TCA cycle related genes in hearts. Role of PPARδ in the regulation of lipid metabolism in heart is then established.
Asunto(s)
Metabolismo de los Lípidos/efectos de los fármacos , Miocardio/metabolismo , Miocitos Cardíacos/metabolismo , PPAR delta/metabolismo , Tiazoles/farmacología , Animales , Animales Recién Nacidos , Ciclo del Ácido Cítrico/efectos de los fármacos , Ciclo del Ácido Cítrico/genética , Ácidos Grasos/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Metabolismo de los Lípidos/genética , Masculino , Miocitos Cardíacos/efectos de los fármacos , Oxidación-Reducción/efectos de los fármacos , PPAR delta/genética , Ratas , Ratas Wistar , Transducción de Señal/efectos de los fármacos , Transducción de Señal/genéticaRESUMEN
We employed streptozotocin-induced diabetic rats (STZ-diabetic rats) as type 1 diabetes-like animal models to investigate the mechanism(s) of antihyperglycemic action produced by syringin, an active principle purified from the rhizome and root part S of ELEUTHEROCOCCUS SENTICOSUS (Araliaceae). Bolus intravenous (i. v.) injection of syringin dose-dependently decreased the plasma glucose of STZ-diabetic rats in 30 minutes in a way parallel to the increase of plasma beta-endorphin-like immunoreactivity (BER). Syringin enhanced BER release from the isolated adrenal medulla of STZ-diabetic rats in a concentration-dependent manner from 0.001 to 10 micromol/l. Bilateral adrenalectomy in STZ-diabetic rats eliminated the activities of syringin (1 mg/kg, i. v.) including the plasma glucose-lowering effect and the plasma BER-elevating effect. Also, syringin failed to lower plasma glucose in the presence of micro-opioid receptor antagonists and/or in the micro-opioid receptor knockout diabetic mice. In conclusion, the obtained results suggest that syringin can enhance the secretion of beta-endorphin from adrenal medulla to stimulate peripheral micro-opioid receptors resulting in a decrease of plasma glucose in diabetic rats lacking insulin.
Asunto(s)
Diabetes Mellitus Experimental/tratamiento farmacológico , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Eleutherococcus/química , Glucósidos/uso terapéutico , Hiperglucemia/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Fenilpropionatos/uso terapéutico , betaendorfina/metabolismo , Médula Suprarrenal/efectos de los fármacos , Médula Suprarrenal/metabolismo , Médula Suprarrenal/patología , Adrenalectomía , Animales , Glucemia/efectos de los fármacos , Glucósidos/administración & dosificación , Glucósidos/farmacología , Hipoglucemiantes/farmacología , Inyecciones Intravenosas , Masculino , Ratones , Ratones Noqueados , Fenilpropionatos/administración & dosificación , Fenilpropionatos/farmacología , Fitoterapia , Ratas , Ratas Wistar , Receptores Opioides mu/antagonistas & inhibidores , Receptores Opioides mu/deficiencia , Estreptozocina , Extractos de TejidosRESUMEN
Previously, we have used the biochemical receptor binding method to investigate whether down-regulation of the opioid receptor is a mechanism for morphine tolerance, and we were led to a negative conclusion. In the current study, we further used immunohistochemistry to reinvestigate this issue. Male Sprague-Dawley rats (250-300 g) were chronically treated with morphine s.c. for 2, 4 or 6 days, using an escalating dosage paradigm (5-45 mg), which resulted in a 1.8 to 4.0-fold increase in AD50. Rat brains were removed, frozen, coronally sectioned (14 microm) and processed for mu- or delta-opioid receptor immunohistochemistry using the Avidin-Biotin Complex (ABC) method. No significant decrease in mu-opioid receptor (MOR) immunodensity was found in most of the brain regions, which were enriched with MOR after chronic treatment with morphine except for the anteroventral thalamic nucleus in the ventrolateral part (AVVL). No significant change in delta-opioid receptor (DOR) immunodensity after chronic treatment with morphine was found either. Therefore, our conclusion is that down regulation of opioid receptors may not be an important mechanism for morphine tolerance.
Asunto(s)
Encéfalo/metabolismo , Dependencia de Morfina/metabolismo , Morfina/farmacología , Receptores Opioides/metabolismo , Animales , Encéfalo/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Inmunohistoquímica , Masculino , Ratas , Ratas Sprague-Dawley , Receptores Opioides delta/metabolismo , Receptores Opioides mu/metabolismo , Factores de TiempoRESUMEN
A field trial to evaluate the efficacy of an oral vaccinia-rabies glycoprotein recombinant virus vaccine in controlling epidemic raccoon (Procyon lotor) rabies was conducted by distributing 180,816 doses (10(8.2)TCID50/ml) of vaccine in wax ampules within fish-meal polymer baits at a rate of 64 doses/km2/treatment throughout a 552 km2 area, forming an 18 km wide band across the northern Cape May Peninsula of New Jersey (USA). Vaccination treatments were conducted in the spring and fall between May 1992 and October 1994 from a helicopter along ecotones and from motor vehicles along roads. Vaccine-laden baits were removed by animals from tracking stations within 3 wk and 61% of the identifiable tracks were those of raccoons. Tetracycline incorporated in the baits as a biomarker was detected in 155 (73%) of the vaccination area raccoons following the fall 1993 and spring 1994 vaccinations. Eleven (61%) of the raccoons sampled in the same time period seroconverted (> or = 0.5 IU) in response to rabies virus glycoprotein. A raccoon diagnosed with rabies from the northern border of the vaccination area on 30 April 1993 provided the first evidence that the barrier was being challenged by the rabies epidemic. The prevalence of rabies in raccoons from the vaccination area for the first year (10%, n = 96) and second year (8%, n = 61) of challenge was reduced more than six-fold by vaccination compared to unvaccinated raccoons from northern adjacent surveillance areas during the corresponding first (65%, n = 189) and second years (53%, n = 43). Vaccination also effectively reduced by three-fold the rate at which the epidemic moved through the raccoon population (15 km/yr). The breach of the vaccination area resulted in a resumption of the high rate (43 km/yr) of epidemic movement and a significant nine-fold increase in rabies prevalence (77%, n = 47). The maximum linear movement (12.9 km) among five ear-tagged rabid raccoons in the study area was significantly greater than that of 19 normal radio-collared raccoons (2.58 km) in the area. These large movements of rabid raccoons, together with relocation of nuisance raccoons, spillover of raccoon rabies in skunks (Mephitis mephitis) and other species, insufficient funding and a decision to discontinue the program in 1994 (which could have resulted in insufficient population immunity among raccoons in the vaccination area) may have contributed to the eventual breach of the barrier.
Asunto(s)
Brotes de Enfermedades/veterinaria , Vacunas Antirrábicas , Rabia/veterinaria , Mapaches , Vacunación/veterinaria , Vacunas Sintéticas , Administración Oral , Animales , Brotes de Enfermedades/prevención & control , New Jersey/epidemiología , Prevalencia , Rabia/epidemiología , Rabia/prevención & control , Vacunas Antirrábicas/administración & dosificación , Vacunas Antirrábicas/normas , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/normas , Virus VacciniaRESUMEN
With the emergence of raccoons (Procyon lotor) as the primary rabies reservoir in the United States of America, a recombinant vaccinia-rabies glycoprotein (V-RG) virus vaccine was developed that protected raccoons by the oral route from rabies infection. Despite extensive laboratory evaluation, vaccine safety concerns remained about free-choice distribution for wildlife rabies control. In this study, the oral innocuity of V-RG virus was demonstrated in immunodeficient mice but parenteral exposure resulted in systemic and progressive infection, albeit significantly abrogated in severity in comparison to vaccinia virus. Treatment with vaccinia immune globulin and hydroxyphosphonylmethoxy-propyl-cytosine resulted in significantly longer survival and minimized V-RG viral gross lesions.
Asunto(s)
Vacunas Antirrábicas/inmunología , Rabia/prevención & control , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/inmunología , Vaccinia/prevención & control , Vacunas Virales/administración & dosificación , Vacunas Virales/inmunología , Administración Oral , Animales , Femenino , Inyecciones Intradérmicas , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Ratones SCID , Rabia/virología , Virus de la Rabia/inmunología , Proteínas Recombinantes de Fusión/inmunología , Vacunas Sintéticas/efectos adversos , Vaccinia/virología , Virus Vaccinia/inmunología , Vacunas Virales/efectos adversosAsunto(s)
Riñón/metabolismo , Intoxicación por Plomo/metabolismo , Plomo/farmacocinética , Hígado/metabolismo , Compuestos Organometálicos/farmacocinética , Mapaches , Administración Oral , Animales , Riñón/patología , Intoxicación por Plomo/patología , Hígado/patología , Compuestos Organometálicos/administración & dosificación , Distribución TisularRESUMEN
During the field safety evaluation of a vaccinia-rabies glycoprotein recombinant virus vaccine for wildlife, two biomarkers were used to identify potential contact with vaccine-laden baits. Tetracycline, a commonly used and reliable calciphilic tissue marker, was included in a fish-meal polymer bait matrix and was evaluated from post-mortem bone samples. Additionally, an ante-mortem marker was needed to identify, for prospective study, raccoons which had contacted baits and thus, potentially, vaccine. Sulfadimethoxine (SDM) was included in an attractant slurry surrounding the bait, as a novel short-term seromarker. Preliminary laboratory studies in raccoons demonstrated SDM residues for up to one week following ingestion of a single 250 mg dose. During the first six days after bait distribution, 49 individual raccoons were live-trapped in the vaccination area. SDM was detectable in 38 of 49 (77.5%) serum samples. Similarly, 47 of 56 (83.9%) bone samples from raccoons collected in the vaccination area throughout the twelve-month study were tetracycline-positive. Conversely, none of the serum samples (n = 12) from the first six days of the trial nor any of the bone samples (n = 34) from raccoons in the surveillance area were biomarker-positive.
Asunto(s)
Animales Salvajes , Biomarcadores , Vacunas Antirrábicas/administración & dosificación , Mapaches , Vacunación/veterinaria , Administración Oral , Animales , Estudios Prospectivos , Sulfadimetoxina , Tetraciclina , Vacunas Sintéticas/administración & dosificación , VirginiaRESUMEN
Successful field oral vaccination and protection against viral diseases have so far been achieved only with live-attenuated or live-recombinant virus vaccines. In this communication, we present data that demonstrate that a glycoprotein derived from recombinant baculovirus-infected insect cells is efficacious as an oral vaccine. The glycoprotein (G) of rabies virus (Evelyn Rokitnicki Abelseth strain) was abundantly expressed in a baculovirus expression system and oral vaccination of racoons with the baculovirus-expressed G protein resulted in the production of rabies virus-neutralizing antibodies and protection against a lethal challenge with a street rabies virus. The potential for using the baculovirus-expressed G protein for oral immunization of wildlife is discussed.
Asunto(s)
Anticuerpos Antivirales/biosíntesis , Antígenos Virales , Baculoviridae , Glicoproteínas/inmunología , Vacunas Antirrábicas/administración & dosificación , Virus de la Rabia/inmunología , Mapaches/inmunología , Vacunación/veterinaria , Vacunas Sintéticas/administración & dosificación , Proteínas del Envoltorio Viral/inmunología , Administración Oral , Animales , Anticuerpos Antivirales/inmunología , Células Cultivadas , Cricetinae , Glicoproteínas/administración & dosificación , Riñón , Mesocricetus , Mariposas Nocturnas , Rabia/prevención & control , Vacunas Antirrábicas/inmunología , Proteínas Recombinantes de Fusión/inmunología , Vacunación/métodos , Vacunas Sintéticas/inmunología , Proteínas del Envoltorio Viral/administración & dosificaciónRESUMEN
We have mapped a linear epitope recognized by the virus-neutralizing monoclonal antibody 6-15C4 within the primary sequence of the G protein from the Evelyn-Rokitnicki-Abelseth strain of rabies virus. This was accomplished by using fragments of the rabies virus G protein and deduced amino acid sequences of neutralization-resistant variant rabies viruses. The monoclonal antibody 6-15C4 specifically recognized a synthetic peptide (peptide G5-24) which resembles the 6-15C4 epitope in structure. In addition, a tandem peptide constructed from the G5-24 peptide and a dominant TH cell epitope of the rabies virus N protein induced protective immunity against lethal rabies virus challenge infection in mice.
Asunto(s)
Antígenos Virales , Epítopos/genética , Glicoproteínas/genética , Virus de la Rabia/genética , Proteínas del Envoltorio Viral , Proteínas Virales/genética , Secuencia de Aminoácidos , Anticuerpos Monoclonales/inmunología , Anticuerpos Antivirales/inmunología , Formación de Anticuerpos , Secuencia de Bases , Epítopos/análisis , Genes Virales , Variación Genética , Glicoproteínas/inmunología , Glicoproteínas/aislamiento & purificación , Activación de Linfocitos , Datos de Secuencia Molecular , Pruebas de Neutralización , Péptidos/síntesis química , ARN Viral/genética , Virus de la Rabia/inmunología , Linfocitos T Colaboradores-Inductores/inmunología , Vacunas Sintéticas , Proteínas Virales/inmunología , Proteínas Virales/aislamiento & purificación , Proteínas Estructurales Virales/genéticaRESUMEN
Immunization of mice and hamsters with a cocktail of mouse MAbs specific for rabies virus nucleocapsid protein and glycoprotein protected animals not only when challenged with a lethal dose of rabies virus after immunization, but also in post-exposure situations. Hamsters treated with the MAb cocktail 3 h after virus inoculation were completely protected from lethal rabies virus infection, and 80% of the animals survived when the MAb cocktail was given 36 h after virus challenge. The potential usefulness of this MAb cocktail for the postexposure treatment of human rabies is discussed.